CDMO Avid Bioservices Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 31, 2014

 

---

PEREGRINE PHARMACEUTICALS, INC. 

(Exact name of registrant as specified in its charter)

 

Delaware		0-17085		95-3698422
(State of other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
14282 Franklin Avenue, Tustin, California 92780
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (714) 508-6000
Not Applicable
(Former name or former address, if changed since last report)

---

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o            Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01        Other Events.

 

Peregrine Pharmaceuticals, Inc. reports that it raised $27.4 million in net proceeds during the quarter ended January 31, 2014 under an At Market Sales Issuance Agreement and ended the quarter with over $63 million in cash and cash equivalents. During the quarter ended January 31, 2014, the Company sold 16,045,717 shares of common stock at an average selling price of $1.75 per share before deducting commissions. The Company will report financial results for the third quarter of its fiscal year 2014 ended January 31, 2014 on March 7, 2014.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	PEREGRINE PHARMACEUTICALS, INC.
Date: February 6, 2014	By:    /s/ Paul J. Lytle
	Paul J. Lytle
	Chief Financial Officer